T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccinationNiels J M Verstegen, Ruth R Hagen, Christine Kreher, Lisan H Kuijper, Jet van den Dijssel, Thomas Ashhurst, Laura Y L Kummer, Virginia Palomares Cabeza, Maurice Steenhuis, Mariël C Duurland, Rivka de Jongh, C Ellen van der Schoot, Veronique A L Konijn, Erik Mul, Katherine KedzierskaSee the full list of authors
28 March 2024
Neurocognitive and psychiatric outcomes associated with postacute COVID-19 infection without severe medical complication: a meta-analysisSarah A B Knapp, David S Austin, Stephen L Aita, Joshua E Caron, Tyler Owen, Nicholas C Borgogna, Victor A Del Bene, Robert M Roth, William P Milberg, Benjamin D Hill
24 June 2024
COVID-19 has no impact on disease activity, progression and cognitive performance in people with multiple sclerosis: a 2-year studyFederico Montini, Agostino Nozzolillo, Nicolò Tedone, Damiano Mistri, Paola MV Rancoita, Chiara Zanetta, Alessandra Mandelli, Roberto Furlan, Lucia Moiola, Vittorio Martinelli, Maria A Rocca, Massimo Filippi,
19 October 2023
Is vaccine response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?Lina Jeantin, Basma Abdi, Cathia Soulié, Delphine Sterlin, Elisabeth Maillart, Ysoline Beigneux, Amandine Hippolyte, Lisa Belin, Anne-Geneviève Marcelin, Valérie Pourcher, Céline Louapre
21 July 2023
Using qualitative free-text data to investigate the lived experience of the COVID-19 pandemic for a large cohort of Australians with different multiple sclerosis related disability levelsJulie A Campbell, Ingrid van der Mei, Bruce V Taylor, Andrew J Palmer, Glen J Henson, Laura Louise Laslett, Steve Simpson-Yap, Suzi B Claflin
26 October 2023
Advances in diagnosis and management of distal sensory polyneuropathiesMatthew Silsby, Eva L Feldman, Richard D Dortch, Alison Roth, Simon Haroutounian, Yusuf A Rajabally, Steve Vucic, Michael E Shy, Anne Louise Oaklander, Neil G Simon
30 March 2023
Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine dosesFrederik Novak, Hamza Mahmood Bajwa, John Eugenio Coia, Anna Christine Nilsson, Christian Nielsen, Dorte K Holm, Kamilla Østergaard, Mathilde Vilhelmine Miller Hvidt, Keld-Erik Byg, Isik S Johansen, Kristen Mittl, William Rowles, Scott S Zamvil, Riley Bove, Joseph J SabatinoSee the full list of authors
25 April 2023
Correspondence on functional neurological disorders after COVID-19 and SARS-CoV-2 vaccinesAmnuay Kleebayoon, Viroj Wiwanitkit
7 April 2023
Functional neurological disorders after COVID-19 and SARS-CoV-2 vaccines: a national multicentre observational studyAraceli Alonso-Canovas, Monica M Kurtis, Victor Gomez-Mayordomo, Daniel Macías-García, Álvaro Gutiérrez Viedma, Elisabet Mondragón Rezola, Javier Pagonabarraga, Lidia Aranzabal Orgaz, Jaime Masjuan, Juan Carlos Martinez-Castrillo, Isabel Pareés
8 March 2023
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with autoantibody-mediated neuroimmunologyKeigo Kihara, Makoto Kinoshita, Tomoyuki Sugimoto, Shuhei Okazaki, Hisashi Murata, Shohei Beppu, Naoyuki Shiraishi, Yasuko Sugiyama, Toru Koda, Tatsusada Okuno, Hideki Mochizuki
3 January 2023
